|| Home||| Journal||| Directories||| Resources||| MAGI||| About Us||| Contact Us||| Sign In||| Sign Up|
FDA - Monitoring Postmarketing Study CommitmentsFDA concurred with two of our three recommendations. Specifically, FDA agreed with our recommendations to improve the management information system for monitoring postmarketing study commitments and to ensure that postmarketing study commitments are being monitored and ASRs are validated. The agency highlighted ongoing efforts to enhance its postmarketing study commitment database and reporting capabilities, train its review division staff on ASR validation procedures, and standardize the process by which postmarketing study commitments are requested and reviewed.
FDA disagreed with our recommendation that it instruct drug applicants to provide additional, meaningful information in their ASRs, citing that implementing such a recommendation would require new regulations.
OFFICE OF INSPECTOR GENERAL RESPONSEIn disagreeing with our finding, FDA highlighted several areas in which it has made improvements. We appreciate that FDA has taken steps to improve its monitoring of postmarketing study commitments. However, our review of the postmarketing study commitment database and annual status reports, as well as our interviews with agency officials, demonstrated that FDA cannot readily identify whether or how timely postmarketing study commitments are progressing toward completion for the period of our review.
We recognize that our recommendation that FDA instruct drug applicants to provide additional, meaningful information in their ASRs could require regulatory changes. In response, we added language to our recommendation acknowledging that FDA may need to seek regulatory changes to improve its system for monitoring postmarketing study commitments.
We also made other minor changes to our report based on FDA’s technical comments.
TABLE OF CONTENTS
EXECUTIVE SUMMARY INTRODUCTION EXTENT OF COMMITMENTS FINDING FDA cannot readily identify progress Missing or incomplete information Limited utility of information Ineffective management information system Monitoring is not a top priority RECOMMENDATIONS Agency comments Office of Inspector General response ENDNOTES APPENDIXES A: Methodology B: Data Tables C: Agency Comments ACKNOWLEDGMENTS
1. To determine the extent to which new drug applications involve postmarketing study commitments with the Food and Drug Administration (FDA).
|© 2003-2012 First Clinical Research LLC. Trademark Notice Terms & Conditions Privacy Statement Site Map|